

Montréal

6TH World Congress of
Cutaneous Lymphomas

J U N E 2 5 - 2 7 , 2 0 2 6

International Society for
Cutaneous Lymphomas



2026 Exhibit and Sponsor Guide



www.6WCCL.org

SPONSOR ACKNOWLEDGEMENT

This program has received an education grant from the following organizations:

Platinum Sponsors

Kyowa Kirin

Therakos LLC, Inc.

Gold Sponsor

Citius Oncology

Silver Sponsors

Bausch Health, Canada Inc.

Helsinn

Pfizer Canada

Supporting Sponsors

Dren Bio

HAC Pharma

SciTech Development

SecuraBio




THURSDAY, JUNE 25	FRIDAY, JUNE 26	SATURDAY, JUNE 27
07:00 - 20:00 Exhibits open	07:00 - 18:30 Exhibits open	07:15 - 11:00 Exhibits open
07:00 - 08:00 Breakfast	07:00 - 08:00 Breakfast	07:15 - 08:15 Breakfast
10:00 - 10:40 Coffee break	10:15 - 10:55 Coffee break	10:15 - 10:55 Coffee break
12:00 - 13:15 Lunch buffet	12:30 - 13:55 Lunch buffet	12:55 - 13:55 Lunch buffet served in the Montréal Foyer
17:30 - 18:30 Poster Session, Chaired by Dr. Paula Enz Even numbered authors standby	17:30 - 18:30 Poster Session Chaired by Dr. Pablo Ortiz-Romero Odd numbered authors standby	
18:00 - 20:00 Welcome Reception		

WIFI

Network: Westin_Conference

PW: Westin2026

NOTE: *pw is case-sensitive*

SPONSORS AND EXHIBITORS LISTING

Bausch Health, Canada Inc. | TABLE: 9

Bausch Health, Canada Inc., headquartered in Laval, Quebec, is part of Bausch Health Companies Inc. (NYSE/TSX: BHC), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes. Bausch Health, Canada Inc. is a leader in the medical dermatology market in Canada and provides treatments for chronic weight management, allergy, neuroscience, and cardio-metabolic conditions. Our two manufacturing facilities in Canada are for prescription pharmaceuticals, including many of our leading dermatological products. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees, and investors.

W: www.bauschhealth.ca

Information for Canadian health professionals is available at www.bauschhealthresources.ca.

Canadian Skin Lymphoma Network | TABLE: 5

W: <https://www.skinlymphoma.ca/>

Citius Oncology | TABLE: 17

Citius Oncology (NASDAQ: CTOR) is a start up biopharmaceutical company focused on commercializing innovative targeted oncology therapies. The company has launched LYMPHIR™ (denileukin diftitox-cxd1), for patients with stage 1-3, relapsed or refractory cutaneous T-cell lymphoma (CTCL) in the US. Please contact us if you have any questions or visit www.lymphir.com.

W: www.lymphir.com

Cutaneous Lymphoma Foundation | TABLE: 2

E: info@clfoundation.org

W: <https://www.clfoundation.org/>

Dren Bio | TABLE: 6

835 Industrial Road, Suite 400

San Carlos, CA 94070

E: info@drenbio.com

W: www.drenbio.com/

European Organization for Research and Treatment of Cancer – Cutaneous Lymphoma Tumour Group | TABLE: 4

Annual EORTC – CLTG Meeting

October 8 – 10, 2026

Berlin, Germany

W: <https://eortc-cltg.org/>

HAC Pharma | TABLE: 13

H.A.C. Pharma aims to be a recognized partner of the medical world by providing therapeutic solutions adapted to the needs of patients and the expectations of healthcare professionals. H.A.C. Pharma works to achieve this goal by maintaining the availability of essential and proven medicines on the market.

T: +33 2 31 47 92 46

W: www.hacpharma.com/en/

Helsinn | TABLE: 10

Helsinn is a global pharmaceutical company focused on supportive care, oncology and dermato-oncology with nearly fifty years of experience. Founded on broad technical expertise, we reach patients worldwide through a unique and diverse commercial and supply network, adding to direct sales in the US.

E: info-HHC@helsinn.com

W: <https://helsinn.com/>

Kyowa Kirin | TABLES: 8 AND 15

We are a Japan-based global specialty pharmaceutical company that uses cutting-edge science to address the needs of patients across multiple therapeutic areas. Our Canadian team shares our values of commitment to life, teamwork, innovation, and integrity to answer the unmet medical needs of patients, their families, and medical professionals.

Lymphoma Canada | TABLE: 3

T: (905) 858-5967

Toll Free: 1-866-659-5556

E: info@lymphoma.ca

W: www.lymphoma.ca

Pfizer Canada ULC | TABLE: 20

Pfizer Canada ULC is the Canadian affiliate of Pfizer Inc., a leading global biopharmaceutical company. We apply science and global resources to deliver therapies that extend and improve lives, setting high standards for quality, safety, and value across discovery, development, manufacturing, and a diversified portfolio of medicines and vaccines worldwide.

To learn more about Pfizer Canada, visit pfizer.ca or follow us on LinkedIn, Facebook, X, Instagram or YouTube.

W: www.pfizer.ca/en

SciTech Development LLC | TABLE: 14

Address: PO Box 36927

Grosse Pointe Farms, MI 48236

W: www.scitechdevelopment.com/

Secura Bio | TABLE: 7

W: <https://securabio.com>
E: info@securabio.com

Therakos LLC | TABLE: 11/12

Therakos LLC specializes in photopheresis technology and has the only FDA approved extracorporeal photopheresis treatment in the US.

To help support our customers in delivering extracorporeal photopheresis to patients, Therakos LLC is available to provide device training and maintenance.

Please see full Prescribing Information, including the BOXED WARNING for UVADEX (methoxsalen) Sterile Solution at www.therakos.com/pi and see the THERAKOS Photopheresis System Operator's Manual.

W: www.therakos.com

United States Cutaneous Lymphoma Consortium (USCLC) | TABLE: 19

Association Executive: Sharon Kim
E: usclc-exec@pamedsoc.org
W: <https://www.usclc.org/>

POSTERS

CHALLENGING CASES OF CUTANEOUS LYMPHOMAS

- P01 Importance of excisional biopsy for diagnosing EBV-positive diffuse large B-cell lymphoma, not otherwise specified presenting with extensive histologic necrosis
Hamada, Toshihisa | *Department of Dermatology, International University of Health and Welfare* | Narita, Japan
- P02 From Benign to Neoplastic: Evolution of Cutaneous Lymphoid Hyperplasia into Primary Cutaneous Marginal zone lymphoma.
Enz, Paula A. | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina
- P03 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation – report of 3 cases
Guenova, Emmanuella | *Department of Translational Immunodermatology, Kepler University Hospital, Johannes Kepler University* | Linz, Austria
- P04 Cutaneous T-cell lymphoma developing in surgical scars post cardiac surgery
Litvinov, Ivan V. | *St. Mary's Hospital Centre, McGill University* | Montréal, Canada
- P05 Long-term Development of Multiple Keratinocyte Malignancies Following Narrowband UVB Therapy for Mycosis Fungoides
Fujii, Kazuyasu | *Kindai University Hospital* | Sakai, Japan
- P06 Granulomatous Slack Skin-Like Cutaneous T-Cell Lymphoma in a 14-Year-Old With Hodgkin Lymphoma: A Rare Pediatric Presentation
Ghafari, Ghazal | *Geisinger Health System* | Danville, USA

- P07 Langerhans cell histiocytosis (LCH) with unusual skin presentation: a dangerous mimic of erythrodermic primary cutaneous T-cell lymphoma/Sézary Syndrome
Pehr, Kevin | *Div. of Dermatology, McGill University. Lady Davis Institute for Medical Research* | Montréal, Canada
- P08 Unilesional Granulomatous Mycosis Fungoides: Case Report in a Young Patient
Reculé, Francisca | *Clinica Alemana and Universidad del Desarrollo* | Santiago, Chile
- P09 Cutaneous T-cell lymphomas linked to treatments with new biological agents and small molecules
Enz, Paula A. | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina

CLASSIFICATION / EPIDEMIOLOGY / PROGNOSTIC FACTORS

- P10 Clinicopathologic Discordance in Folliculotropic Mycosis Fungoides: Clinical Relevance and Outcome Associations
Bui, Toan | *Johns Hopkins University* | Baltimore, USA
- P11 B2 mycosis fungoides, not always Sézary
Cury Martins, Jade | *University of São Paulo* | São Paulo, Brazil
- P12 Prevalence of human T cell lymphotropic virus 1 infection in Canada
Litvinov, Ivan V. | *St. Mary's Hospital Centre, McGill University* | Montréal, Canada
- P13 Clonal Granulomatous Dermatitis Associated With Myeloid Neoplasms: A Clinicomolecular Study of 16 Patients
Battesti, Gilles | *Dermatology, Saint Louis Hospital, Paris APHP France* | Paris, France

- P14 Localised Primary Cutaneous Gamma-Delta T-Cell Lymphoma
Tee, Shang-lan | *National Skin Centre* | Singapore, Singapore
- P15 Primary Cutaneous B-Cell Lymphomas: A 13-Case Series from a Referral Center in Buenos Aires, Argentina
Enz, Paula A. | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina
- P16 Candidate Tumor Markers of Cutaneous T-cell Lymphomas Identified Through Analysis of Two Cases of Peripheral T-Cell Lymphoma, Not Otherwise Specified
Honda, Ryoma | *International University of Health and Welfare Graduate School of Medicine* | Narita, Japan
- P17 Primary Cutaneous Lymphomas and Lymphoproliferative Disorders in a Community-Based Oncology Network: Disease Spectrum and Secondary Malignancies
Walker, Christina J. | *Community Health Network* | Indianapolis, USA
- P18 Prognostic Value of Tumor Clone Frequency in Mycosis Fungoides
Nikbakht, Neda | *Department of Dermatology, Hematology, and Medical Oncology, Emory University* | Philadelphia, USA
- P19 Long-term Outcomes and Recurrence Patterns in Primary Cutaneous Marginal Zone Lymphoma and Primary Follicle Centre Lymphoma B-cell Lymphoma
Bashir, Abraham E. | *University Hospitals Birmingham NHS Foundation Trust* | Birmingham, United Kingdom
- P20 Mantle Cell Lymphoma with Cutaneous Involvement: A Systematic literature review
Babana el Alaoui, Ahmadou | *Memorial Sloan Kettering Cancer Center* | New York, USA

PATHOLOGY / BIOMARKERS / MICROENVIRONMENT

- P21 Single-cell-resolution spatial transcriptome profile and prognostic implication of cancer-associated fibroblast in early-stage mycosis fungoides
Lee, Woo Jin | *Asan Medical Center, University of Ulsan College of Medicine* | Seoul, Korea
- P22 A Scoping Review on the Clinical Implications of the Skin Microbiota in the Therapy of Cutaneous T-cell Lymphoma
Czyz, Sonia | *Dept. of Medicine, Cumming School of Medicine, University of Calgary* | Calgary, Canada
- P23 Diagnosis of Cutaneous Lymphomas by T-Cell Clonality Analysis: Comparative Effectiveness of Methods
Gorenkova, Liliya | *The National Research Centre of Haematology* | Moscow, Russia
- P24 JAK-Inhibition As A Novel Multilevel Treatment Of Cutaneous T Cell Lymphoma
Pourjafar, Mona | *Department of Clinical Medicine, The Department of Dermatology and Venereology, Aarhus University Hospital* | Aarhus, Denmark

- P25 Phenotypic switching in mycosis fungoides/Sézary syndrome patients: clinical implications and survival outcomes in four Brazilian cases
Miyashiro, Denis | *Department of Dermatology, University of São Paulo Medical School* | São Paulo, Brazil
- P26 Tumor-informed ctDNA MRD monitoring correlates with cutaneous lesion evolution and PET response in stage IIB mycosis fungoides
Rouf, Rejowana | *Mount Sinai Hospital* | New York, USA
- P27 Dissecting immune determinants in lesional skins of cutaneous T-cell lymphoma during Mogamulizumab therapy
Ni, Xiao | *Dept. of Dermatology, The University of Texas MD Anderson Cancer Center* | Houston, USA

QUALITY OF LIFE / PATIENT REPORTED OUTCOMES

- P28 Quality-of-Life and Supportive-Care Interventions in Mycosis Fungoides and Sézary Syndrome: A Scoping Review
Bouchi, Yazan A. | *Morehouse School of Medicine* | Atlanta, USA
- P30 Content Validity of Itch Patient-Reported Outcome Measures in Cutaneous T-Cell Lymphoma: A COSMIN-guided Qualitative Study
Park, Jenny J. | *Department of Dermatology, University of Washington* | Seattle, USA
- P31 Overcoming barriers to bathing care for patients with cutaneous lymphoma: observations from 25 years of nursing care in an Australian quaternary referral centre.
Buelens, Odette C. | *Peter MacCallum Cancer Centre* | Melbourne, Australia
- P32 Health-Related Quality of Life in Cutaneous T-Cell Lymphoma Treated With Multimodality Therapy Including Extracorporeal Photopheresis: A Latin American Experience
Enz, Paula A. | *Hospital Italiano de Buenos Aires* | Buenos Aires, Argentina
- P33 Quality of Life in Cutaneous T-Cell Lymphoma: Current Insights and Future Directions
Vermeer, Maarten | *LUMC, Leiden* | Leiden, Netherlands
- P34 Evaluation of an educational video to support understanding of health-related quality of life for patients with cutaneous T-cell lymphoma
Nayudu, Krithika | *Medical College of Georgia* | Augusta, USA; *Mass Brigham General* | Boston, USA

THERAPEUTICS / PRECLINICAL STUDIES

- P35 Treatment Outcomes and Recurrence Patterns Following Local Therapies in Primary Cutaneous Marginal Zone and Follicle Center Lymphoma
Gonzalez, Sarah M. | Department of Dermatology, Dartmouth-Hitchcock Medical Center | Lebanon, USA
- P36 Comprehensive Characterization of DT-7012, a Highly Differentiated Anti-CCR8 Depleting Antibody in CTCL
Sabbagh, Laurent | Kainova Therapeutics | Montréal, Canada
- P37 Post hoc analysis of a randomized, controlled, phase 2 study to assess the efficacy of chlormethine gel in patients with early-stage mycosis fungoides based on skin phototype
Rozati, Sima | Johns Hopkins University School of Medicine | Baltimore, USA
- P38 EORTC 1820-MOGAT – Mogamulizumab Plus Total Skin Electron Beam Therapy in Patients with stage IB-IIB Cutaneous T-Cell Lymphoma
Ortiz-Romero, Pablo L. | Hospital Universitario 12 de Octubre | Madrid, Spain
- P39 Use of Immune Checkpoint Inhibitors in Refractory Mycosis Fungoides and Sézary Syndrome: A Systematic Review
Litvinov, Ivan V. | St. Mary's Hospital Centre, McGill University | Montréal, Canada
- P40 Real-life efficacy of immunotherapy for Sézary syndrome: a multicenter observational study
Bozonnat, Alizée | Department of Dermatology, Saint-Louis Hospital, AP-HP, INSERM U976, Université Paris Cité | Paris, France
- P41 Mogamulizumab: Real-World Experience in Heavily Treated Patients With Mycosis Fungoides and Sézary Syndrome: Durable Efficacy and Tolerability
Alabdulkareem, Ahmad | Division of Dermatology, McGill University | Montréal, Canada
- P42 A phase 1, multicenter, prospective, first-in-human dose-escalation clinical trial of anti-CCR8 monoclonal antibody DT-7012 in patients with relapsed or refractory CTCL
Beylot-Barry, Marie | Department of Dermatology, CHU de Bordeaux – INSERM 1312, University of Bordeaux | Bordeaux, France
- P43 BUFALLO is a novel reduced intensity conditioning regimen for the allogeneic stem cell transplantation for patients with primary cutaneous T-cell lymphomas
Gorenkova, Liliya | The National Research Centre of Haematology | Moscow, Russia
- P44 Topical JAK Inhibitors in Early-Stage Mycosis Fungoides: A Systematic Review
Kheirmand, Kimia | Aarhus University Hospital | Aarhus N, Denmark
- P45 Mogamulizumab treatment for mycosis fungoides in clinical practice in France: data from the ongoing multicentric prospective observational PROMED study

- Beylot-Barry, Marie** | Department of Dermatology, CHU de Bordeaux – INSERM 1312, University of Bordeaux | Bordeaux, France
- P46 Combination Low-dose Radiotherapy and Topical Imiquimod May Stimulate a Systemic Anti-tumor Response in Mycosis Fungoides
De Jong, Katherine | Northwestern University | Chicago, USA
- P47 New Onset and Rapid Progression of Cutaneous T-Cell Lymphomas in Association with Immune Checkpoint Inhibitor Therapy: A Systematic Review
Babana el Alaoui, Ahmadou | Memorial Sloan Kettering Cancer Center | New York, USA

LATEBREAKING

- P48 Disproportionate Representation of Intellectual Disability and Higher Fitzpatrick Skin Types Among Patients Presenting with Tumor-Stage Cutaneous T-Cell Lymphoma
Lapolla, Brigit A. | Columbia University | New York, USA
- P49 Deruxtecan-based antibody-drug conjugate targeting TCR-Vβ2 for the treatment of cutaneous T cell lymphoma
Kwang, Alexa | Yale University | New Haven, USA
- P50 Primary cutaneous innate lymphoid lymphoma
Zhang, Yue | Memorial Sloan Kettering Cancer Center | New York City, USA
- P51 Epidermotropic, cytotoxic, ALK+ T-cell lymphoma: appraisal of a discrete pattern of disease
Croci, Giorgio Alberto | University of Milan | Milano, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico | Milano, Italy
- P52 Adult T-Cell Leukemia/Lymphoma Emerging During Dupilumab Therapy for Severe Atopic Dermatitis: Should We Screen for HTLV-1?
Millán, Rocío | Pontificia Universidad Católica de Chile | Santiago, Chile
- P53 Adult T-Cell Leukemia/Lymphoma Mimicking Indolent Cutaneous Lymphoma: The Role of HTLV-1 and Re-biopsy in Endemic Regions
Millán, Rocío | Pontificia Universidad Católica de Chile | Santiago, Chile
- P54 Imaging Beyond Staging in Primary Cutaneous Marginal Zone Lymphoma: Interim Analysis of a Multi-Institutional Retrospective Study
Zhou, Maggie H. | Columbia University Vagelos College of Physicians and Surgeons | New York, USA
- P55 Cutaneous and peripheral T-cell lymphomas increase the risk of cardiovascular and thromboembolic events: A retrospective TriNetX cohort study
Nicolay, Jan P. | University Medical Center Mannheim | Mannheim, Germany
- P56 IL4Rα blockade inhibits proliferation of malignant lymphocytes and the immunosuppressive tumor microenvironment of mycosis fungoides
Fuschiotti, Patrizia | University of Pittsburgh | Pittsburgh, USA

International Society for
Cutaneous Lymphomas



JOIN THE ISCL!

We encourage you to join the International Society for Cutaneous Lymphomas, the organizing society of the World Congress of Cutaneous Lymphomas. The ISCL is dedicated to the treatment, research and caring of patients with cutaneous lymphomas. The ISCL was founded in 1992 at the World Congress of Dermatology in New York and among its aims are to increase knowledge of lymphoproliferative and related disorders of the skin, foster collaboration among clinicians and scientists, and promote dissemination of scientific information.

To apply for membership, visit <https://cutaneouslymphoma.org/about-membership/> or scan the QR code.



ISCL HEADQUARTERS

675 Tollgate Rd., Suite G, Elgin, IL
60123 USA
Phone: +1-312-585-8941
www.cutaneouslymphoma.org

